Wintergreen's 7th S-4 Amendment Adds KIKA FY2026 Financials and $5-10M PIPE Commitment
WTG is trading near its 52-week low of $9.74 (9.1% above the low) on light trading volume (0.1× avg).
Summary
Wintergreen's latest S-4 amendment discloses KIKA's audited FY2026 financials showing revenue surged to $21.84M, plus a $5-10M PIPE commitment to support the merger closing.
Key Events · M&A and Partnerships · WTG
-
KIKA FY2026 Audited Financials Disclosed
KIKA reported FY2026 revenue of $21.84M (up 1,567% from $1.31M in FY2025) and net income of $683,578, with gross margin declining to 30.8% from 44.9% due to volume-tiered pricing.
-
$5-10M PIPE Commitment Secured
KIKA has engaged prospective investors who committed to purchase between $5 million and $10 million of shares upon merger completion to offset potential high redemption rates.
-
Second Extension Note Issued
Sponsor issued a second $184,635 unsecured note on September 28, 2026, extending the business combination deadline to October 30, 2026 (aggregate $369,270 in extension notes).
-
Customer Concentration Risk Quantified
Four key clients accounted for 66% of FY2026 revenue ($14.4M), with customer retention rate declining to 9% from 29% in FY2025.
Analysis · WTG · Life Sciences
This seventh amendment to the KIKA merger S-4 adds material new information: KIKA's audited FY2026 revenue of $21.84M (up from $1.31M in FY2025), net income of $683,578, and a disclosed commitment from prospective investors to purchase $5-10M of shares at closing to mitigate redemption risk. The filing also reveals the second sponsor extension note of $184,635 issued September 28, 2026, extending the deadline to October 30, 2026. The 66% customer concentration from four key clients and the 93.28% redemption threshold are newly quantified risk factors. This is not a routine reiteration — it provides the first audited financials and concrete financing commitments for the pending merger.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 28.9% of the 1476 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, WTG was trading at $10.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.2M. The 52-week trading range was $9.74 to $10.63. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.